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OBJECTIVE To investigate whether the progression rate of asthma or chronic bronchitis can be 
predicted from a cross-sectional assessment of features that can be measured by family physicians.
DESIGN Secondary analysis of data from a 2-year randomized, controlled broncho dilator 
intervention study in family practice.
SETTING Twenty-nine general practices in the eastern part of The Netherlands.
PATIENTS One hundred sixty padents (101 with chronic bronchitis, 59 with asthma) from the 
29 general practices.
INTERVENTIONS Predictors were related to the annual decline in lung function (the forced expiratory 
volume in one second) by means of multiple analysis of variance, controlling for age, sex, smoking 
habits, initial FEVj level, bronchial hyperresponsiveness, reversibility of obstruction, and 
medication during the study.
MAIN OUTCOME MEASURES Predictors of the annual decline in lung function (FEV^, which is believed 
to be the most important measure for progression.
RESULTS Only three variables predicted the decline in lung function: having a barrel-shaped 
chest, experiencing wheezing, and an unusual diurnal peak-flow rate index. Wheezing was the 
best predictor of the annual decline in lung function. In chronic bronchitis, the decline in FEV[ 
of wheezing patients was 133 mL/y compared with 62 m L/y for non-wheezing patients 
(P < 0.05). In asthma with more severe symptoms, wheezing patients had a tendency to decline 
156 m L /y compared with 57 m L /y among non-wheezing patients (P = 0.08).
CONCLUSIONS It is nearly impossible to predict the progression rate of asthma or chronic bronchitis 
from symptoms, physical signs of the chest, and the PEFR. Therefore, patients with a rapid 
progression rate can probably be detected only by monitoring progression of the disease through 
repeated lung function testing.
D r  v a n  S c h a y c k
is a Research Coordinator,
D r  D o m p e l i n g
is a Research Fellow,
D r  P u t t e r s  is a Research 
Fellow\ and D r  v a n  W e e l  
is Department Head in the 
Department o f General 
Practice, and D r  M o l e m a  
is a Chest Physician in the 
Department o f Pulmonary 
Diseases, at the University o f  
Nijmegen in The Netherlands.
OBJECTIF Analyser si revaluation transversale des caractéristiques mesurables par les médecins de 
famille peuvent prédire le rythme de progression de l’asthme ou de la bronchite chronique.
CONCEPTION Analyse secondaire des données tirées d’une étude randomisée et contrôlée effectuée 
aux Pays-Bas pendant deux ans et utilisant la broncho dilatation comme intervention.
CONTEXTE Vingt-neuf pratiques générales situées dans la partie orientale des Pays-Bas.
PARTICIPANTS Cent soixante patients (101 bronchitiques chroniques, 59 asthmatiques) suivis par 
29 praticiens généraux.
INTERVENTIONS Les facteurs de prédiction furent associés au taux annuel de détérioration de la 
fonction pulmonaire (le volume expiratoire maximum/seconde) au moyen d’analyses multiples de 
variance, de correction en fonction de l’âge, du sexe, des habitudes tabagiques, du VEMS initial, 
de T hyperréactivité bronchique, de la réversibilité de l’obstruction et de la médication utilisée 
pendant T étude.
PRINCIPALES MESURES DES RÉSULTATS Les facteurs de prédiction du taux annuel de détérioration de la 
fonction pulmonaire (VEMS) que l’on considère être la mesure la plus importante pour évaluer la 
progression de la maladie.
#
RESULTATS Seulement trois variables ont pu prédire la détérioration de la fonction pulmonaire: 
thorax en tonneau, présence de sibilances (wheezing) et indice inhabituel du débit de pointe 
diurne. Parmi ces variables, le wheezing s'est avéré le meilleur facteur pour prédire le taux 
annuel de détérioration de la fonction pulmonaire. Dans la bronchite chronique, la détérioration 
du VEMS des patients présentant des sibilances fut de 133mL/année comparativement à 
62 m L/année pour les patients dépourvus de sibilances (p < 0,05). Chez les asthmatiques 
présentant des symptômes plus sévères, la détérioration des patients sibilants fut de 
l56m 'L/année comparativement à 57mL/année chez les non-sibilants (p = 0,08).
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CONCLUSIONS H est presque impossible de prédire le rythme de progression de l’asthme ou de la 
bronchite chronique à partir des symptômes, des signes physiques pulmonaires et de la mesure du 
débit expiratoire de pointe. Le seul moyen probablement capable de détecter une détérioration 
rapide de la maladie consiste à en surveiller la progression par des tests répétés de la fonction 
respiratoire.
Can Fam Physician 1995;41:1868-1876.
STHMA a n d  CHRONIC b r o n c h i t i s  101 patients with chronic bronchitis.
are chronic and progressive 
diseases of the airways.1“3
These patients had participated in a 
2-year bronchodilator tria l.14 D ata
patients
METHODS
The annual decline in lung from this study were used for this 
function is much higher among secondary analysis.
M than in random samples of 
the population.4 At an advanced stage 
of the disease, daily life becom es 
severely limited as a consequence of 
poor lung function.5 Patients with a P a t i e n t s
rapid decline in lung function are One hundred sixty patients (101 with 
particularly at risk of early disability chronic bronchitis, 59 with asthma) 
death from chronic airway participated in a 2-year randomized,or
obstruction.6
Morbidity and mortality due to 
asthma and chronic bronchitis seem to
controlled bronchodilator intervention 
study in family practice.14 At the start 
of the study, 29 fam ily physicians
practice, it is possible that underdiag­
nosis and under treatment contributes
be rising in several countries.7,8 selected all their patients 30 years and 
Because most patients with asthma and older with symptoms of asthma or 
chronic bronchitis are treated in family chronic bronchitis. Only patients who
showed moderate airflow obstruction 
(FEVj or FEVj divided by the expira- 
to this worldwide trend. Effective treat- tory vital capacity had to be 2 SD  
ment of asthma and chronic bronchitis below their predicted value, but more
f  c z
in the form of inhaled corticosteroids is than 50% of predicted value) or 
now available.10'12 Therefore, early bronchial hyperresponsiveness to hista- 
detection (and early treatment) o f mine (provocative concentration of his-
patients at risk (with a fast progression 
rate) is important.13
It is unclear how this can be carried
tamine producing a 20% fall in FEV^ 
were included (PC20 ^ 8 m g/m L ). 
Exclusion criteria were dependence on
out easily and effectively by family corticosteroids, chronic heart failure, 
physicians. Family physicians are limit- malignant disorders, or other severe 
ed in their ability to diagnose the sever- life-threatening diseases.
ity of asthma and chronic bronchitis 
objectively. In general they are able to
The criteria for diagnosis of asthma 
or chronic bronchitis were based on
assess bronchial symptoms, physical the standards o f  the A m erican  
signs of the chest, and the peak expira- Thoracic Society.5,14 All patients gave
tory flow rate (PEFR).
This study aimed to assess whether 
the progression rate of asthma or 
chronic bronchitis can be predicted 
from a cross-sectional assessment of
informed consent. T he study was 
approved by the Ethics Committee of 
the University of Nijmegen.
During the 2-year study period, 
patients received only monotherapy
bronchial symptoms, physical signs with inhaled bronchodilators (salbuta- 
of the chest, PEFR, and diurnal mol or ipratropium bromide). No cor-
(DI-PEFR) or week-to-week (CV-PEFR) 
variation in the PEFR. These indices
ticosteroids were permitted, except 
during exacerbations. All exacerba-
were related to the rate of progression tions were treated in a standard way by 
(annual decline in lung function) family physicians: a broad-spectrum  
for 59 patients with asthma and antibiotic and a 10-day tapering course
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with 5-mg tablets of oral prednisolone examination consisted of inspection
and auscultation during unforced deep 
breathing with open mouth17 and was
(5-5-4-4-3-3-2-2-1-1).
M e a s u r e m e n t s
R esp ira to ry  s y m p to m s . Respira­
tory symptoms were assessed at the 
start of the study with the Medical
Research CounciPs questionnaire and



















performed while patients were upright. 
Presence or absence of the following 
items was noted:
• barrel-shaped chest,
• decreased expiratory breath sounds,
• prolonged expiratory phase,
• wheezing,
P h y s ic a l  e x a m in a tio n . Physical • inspiratory sounds audible without 
examination of the chest by standard- using a stethoscope, 
ized procedure took place during an • fine crackles, or 
exacerbation-free period. All medica- • 
tion was discontinued for at least 
8 hours before examination. The
coarse crackles.
Table L  D e m o g ra p h ic  c h a ra c te r i s t ic s  o f  p a t i e n t s  w i th  c h ro n ic  
b r o n c h i t i s  a n d  a s th m a
ft
Table 2. C lin ic a l  c h a ra c te r i s t ic s  o f  p a t i e n t s  w i th  c h ro n ic  










(N = 101) %
PATIENTS WITH 
ASTHMA 
(N = 59) %
Sex (male) 55 61 47
Allergy 28 19* 44
Smoking 55 62f 42















Age (y) 51(12) 52 (12) 49 (12)
Number of packs 
smoked daily per year 16(16) 18(16)* 12(15)
Symptoms score 4(1) 4(1) 4(1)
FEV! (%) 76(19) 78(17)* 72 (21)
CV-PEFR 7.4 (4.8) 6.5 (4.0)1- 9,2 (5.0)
DI-PEFR
*P < 0.05. 
'P <0.001.
9.3 (6.3) 7.7 (5.0)r 12.0(6.0)
Patients measured their PEFR 
weekly (on the same day and at the 
same time of the day) during 6 weeks, 
using an Assess Peak Flow Meter 
(Health Products Inc, U SA ).18 The 
highest values of a triple measurement 
in the morning and in the evening 
were used for three parameters: the 
mean of the morning PEFR during 6 
weeks; the DI-PEFR (the difference 
between the morning and evening 
PEFR, expressed as a percentage of 
the maximum value of that day); and 
the CV-PEFR (the standard deviation 
expressed as a percentage of the mean 
morning PEFR of 6 weeks).
The FEVj was measured at 
6-month intervals and after 1 and 
13 months o f study by means of 
the Microspiro HI-298 (seven assess­
ments).19 The best of three FEV\ mea­
surements, with the highest sum of the 
forced vital capacity (FVC) and the 
FEVb was used for data analysis.
4
A n a l y s i s
For each patient, the annual decline 
in FEVi was estim ated by linear 
regression of seven assessments of 
FEVj over time.14 The independent 
variables (bronchial symptoms, mean
morning PEFR, DI-PEFR, CV-PEFR,
and physical signs of the chest) were 
related to the annual decline in FEV{ 
by means of multiple analysis of vari­
ance (MANOVA). The possibly con­
founding influence of several variables 
(age, sex, height, smoking history, 
number of packs smoked daily per
1870 Canadian Family Physician VOL 41 : November 1995
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year, bronchodilator therapy during no correlation coefficient could be cal-
the study, FEV\ as a percentage of the culated. Correlation coefficients were
predicted value, PC20, and reversibi- low, both in asthma (r < 0.15) and in
lity of airflow obstruction) was investi- chronic bronchitis (r < 0.21), O nly
gated and, if necessary, controlled for. wheezing sounds in chronic bronchitis
The separate and combined effects of correlated significantly with lung func-
bronchial symptoms and the variation in 
PEFR on the annual decline in lung
tion decline (r = 0,21, P <  0.05).
7able 4 shows estimates of the annual 
function were further quantified by decline in lung function in the multivari- 
dichotomizing the symptom score and ate linear regression model. Only three 
the peak flow variability on the basis of significant relationships were found. In 
rounded mean values (< mean -*• > mean), chronic bronchitis, a barrel-shaped chest
and a high DI-PEFR were related to
RESULTS
greater decline in lung function (estimate 
-166 and -8 mL/y, respectively). In the 
group as a whole, wheezing was accom- 
Patient characteristics are shown in panied by greater decline in lung func- 
Tables 1 and 2. Patients with chronic tion (estimate -70 m L /y). T h e  
bronchitis more often were smokers, percentage of the variance explained by 
had smoked more in the past, were less the model was 43% in asthma, 27% in 
often allergic, and had a lower chronic bronchitis, and 22% in the
DI-PEFR and CV-PEFR than patients 
with asthma.
Correlation coefficients between 
symptoms, peak flow variability, and
group as a whole.
Figure 1 shows the separate and  
combined effects of bronchial symp­
toms with the week-to-week or diurnal
physical signs on the one hand and the variation of the PEFR on the annual
annual rate of decline in FEV! on the 
other are shown in Table 3 . Crackles 
were not present in asthma; therefore, ables. Wheezing sounds were present
rate of decline. All figures in Figure 1 
were adjusted for confounding vari-
Asthma and chronic bronchitis
Table 3. C o r r e l a t i o n  c o e f f ic ie n ts  b e tw e e n  s y m p to m s ,  p h y s i c a l  s i g n s  o f  t h e  c h e s t ,  (v a r ia b i l i ty  in) P E F R , 
a n d  a n n u a l  d e c l in e  in  l u n g  f u n c t io n  in  a s t h m a  a n d  c h r o n ic  b r o n c h i t i s  ( u n iv a r i a t e  a n a ly s is ) :
Pearson's correlation coefficient is usedfor continuous variables, Spearman’s correlation confidentfor other variables.
VARIABLE
PATIENTS WITH CHRONIC 
BRONCHITIS OR ASTHMA
PATIENTS WITH CHRONIC 
BRONCHITIS PATIENTS WITH ASTHMA
Symptom score 0.027 -0.012 0.123
PEFR -0.085 -0.137 0.029
DI-PEFR 0.034 “0.054 0.131
CV-PEFR 0.134 0.179 0.042
Barrel-shaped chest (+ /—) 0.073 0.182 -0.123
Decreased expiratory sounds (+ /-) 0.058 0.084 0.047
Prolonged expiration (+ /—) 0.037 0.013 0.114
Wheezing sounds (+ /—) 0.151 0.214* 0.084
Noisy inspiration (+ /—) -0.017 -0.011 -0.001
Fine crackles (+ /—) -0.006 -0,013
Coarse crackles (+ /—) -0.037 -0.049 ---
*P < 0.05.
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in 18 patients with asthma and
22 patients with chronic bronchitis. In 
chronic bronchitis patients with wheez­
ing, the annual decline in FEVl was
DISCUSSION
Family physicians managing asthma 
ancl chronic bronchitis are often con-
-133 m L /y versus -62 m L/y in non- fronted with patients whose disease
wheezing patients (P < 0.05). This dif- has already w orsened too much,
ference was caused by patients who had Evidence suggests that asthma and
more severe symptoms (-142 mL/y ver- chronic bronchitis are diagnosed too
sus -58 mL/y). In asthma, wheezing late.13,20,21 Morbidity and mortality
also tended to predict decline in lung due to asthma and chronic bronchitis
function, but only among patients with are still rising.7,8 Therefore, early
more severe symptoms (-156 versus detection  and early treatment o f
-57 m L /y  P = 0.08).
We also investigated whether the 
mean morning peak flow rate as per­
centage of predicted values was related 
to lung function decline as a separate
patients at risk (with rapidly progress­
ing disease) is important.13
Our study showed that it is nearly 
impossible to predict the progression 
rate of asthma or chronic bronchitis
factor or in combination with symp- from a cross-sectional assessment of 
toms. Patients who had a peak flow of symptoms, separate physical signs of
the chest, the morning PEFR, and the
DI-PEFR or CV-PEFR. In the multi-
more than 70% had no greater decline 
in lung function than patients with a 
peak flow below 70%. The same holds 
for 50% or 60%. There was no differ­
ence between chronic bronchitis and be explained by all variables investigat-
variate model, only 22% to 43% of the 
variance in lung function decline could
asthma in this respect. eel. This means that our ability to
Table 4. M u l t i v a r i a t e  l i n e a r  r e g r e s s i o n  o f  t h e  r e l a t i o n s h i p  b e t w e e n  s y m p t o m s ,  p h y s i c a l  s ig n s  
o f  t h e  c h e s t ,  ( v a r i a b i l i t y  in )  P E F R ,  a n d  a n n u a l  d e c l in e  in  l u n g  f u n c t io n :  Allfigures were corrected for possibly 
confounding variables.
VARIABLE
PATIENTS WITH CHRONIC 
BRONCHITIS OR ASTHMA ESTIMATED
mL/y (SE)






Symptom score 8(9) 2(9) 7(12)
PEFR 0(0) 0(0) 0(0)
DI-PEFR -2 (0) -8 (4)*
i
3(4)










-166 (81)* 346 ( 184)
Decreased expiratory sounds -28 (35) -46 (43) 22 (65)
Prolonged expiration (+ /- ) 4(40) 32 (46) -27 (68)
Wheezing sounds (+ /—) -70 (33)* -78 (40) -102 (60)
Noisy inspiration (+ /—) 33 (48) 68 (57) 29 (94)
Fine crackles (+ /- ) -57 (45) -58 (43)
Coarse crackles (+ /—) 110(116) 23 (107)
Percentage explained variance 22 27 43
*P < 0.05.
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predict lung function decline is very 
limited and that patients with a fast 
progression cannot be detected from an 
assessment of symptoms, physical signs 
of the chest, and PEFR. Therefore, 
probably the only way to detect these 
patients is to monitor the course of dis­
ease by measuring lung function.
Introducing spirometry in family 
practice could be an important step for­
ward in the long-term management of 
asthma and chronic bronchitis.22 Reliable 
and portable spirometers are available, 
although still rather expensive,19
Early detection is useful only when 
early intervention is available and 
effective. Evidence shows the efficacy 
of inhaled corticosteroids for asthma 
during several months23"25 and during
1 or more years. 11,12,2G‘2}1 Several guide­
lines on the treatment of asthma have 
advised introducing inhaled corticos­
teroids at an early stage of the disease 
and avoiding regular use of bron- 
chodilators.10,29,30 There is also some 
evidence for the efficacy of inhaled 
steroids among patients with chronic 
bronchitis.11,12 After our study, we per­
formed a 2-year trial with inhaled  
beclomethasone (800 \lg daily) for the 
56 patients with a rapid progression 
rate.12 We observed that rapid progres­
sion among these patients was deceler­
ated by the use of the inhaled steroid 
for both asthma and chronic bronchi­
tis. Therefore, early intervention with 
inhaled steroids appeared to be effec­
tive for these patients at risk.
The only parameters that coulcl to 
some extent predict a rapid decline in 
lung function were a barrel-shaped 
chest, the presence of wheezing, and 
the DI-PEFR. The correlation  
between wheezing and the decline in 
lung function is interesting. Although 
wheezing is assumed to be a typical 
feature of asthma, it is also a sign of 
chronic bronchitis.5 Gross-sectional 
assessments have shown that wheezing 
correlates with airflow obstruction only 
in patients with chronic bronchitis.17,31 
W heezing was more likely to be 
present in asthma but did not signify 
the presence or absence o f airflow
I *7obstruction. In this study, the pres­
ence of wheezing was mainly related 
to an increased annual decline in 
lung function among patients with 
chronic bronchitis.
The presence o f  a barrel-shaped 
chest is supposed to be typical for 
hyperinflation and could indicate some 
degree of emphysematous changes.5 
Burrows and co-workers32 demonstrated 
that patients with a diagnosis of emphy­
sema had a substantial annual decline 
in lung function exceeding that of 
patients with other types of chronic 
obstructive airways disease. Emphysema 
was not excluded in our study, and it is 
therefore possible that some bronchitis 
subjects in this study already had some 
emphysematous changes. This probably 
explains the correlation between a 
barrel-shaped chest and a rapid decline 
in lung function.
These findings together suggest that 
physical signs of the chest, at least the 
signs of barrel-shaped chest and 
wheezing, to some extent reflect the 
presence of airflow obstruction17,31 and 
also have some predictive value for the 
course of airflow obstruction. It was 
interesting that a prolonged expiratory 
phase, which is widely accepted as the 
most direct sign of airflow obstruc­
tion,31 was in no way related to a pro­
nounced decline in lung function.
The DI-PEFR showed a significant 
correlation with the annual rate o f  
decline among patients with chronic 
bronchitis. Although the variability of 
the peak flow (both diurnal and week- 
to-week) was much higher in asthma 
than in chronic bronchitis, this vari­
ability did not predict lung function 
decline better in asthma. The vari­
ability in peak flow  (and airway  
obstruction) is related to the airway 
responsiveness to bronchoconstrictive 
and bronchodilating stimuli, as they all 
probably express instability of the air­
ways.33 This particularly is the case in 
asthma. Inflammation is an underlying 
mechanism of airway instability. It has 
been shown before that instability of 
the airways in asthma, as assessed by 
means of the bronchial responsiveness
R E S E A R C H
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to histamine, predicts a rapid annual 
decline in lung function.3
The mean morning PEFR was not a 
good predictor for the annual rate of 
decline in lung function in this study, 
though it is an effective and essential 
tool for managing chronic persistent 
asthma29 and acute severe asthma,34 
and for self-management plans of asth­
ma.35 Burrows et al36 investigated the 
predictive value of screening spirome­
try for the annual decline in FEVj in a 
sample from the general population. 
They also observed that one assess­
ment of spirometry was not reliable 
enough to detect the patients at risk, 
particularly am ong wom en. More 
measurements of lung function over 
time will probably make detecting 
patients with asthma and chronic 
bronchitis more reliable.
A disadvantage of a reanalysis is 
that results are used from a study not 
originally set up for this purpose and, 
therefore, can serve only as an obser­
vational study. No natural course of 
the disease was studied, as the patients 
used in this study were treated with 
bronchodilators. However, all figures
X
were controlled for bronchodilator 
use. We saw no significant influence of 
medication. With this limitation in 
mind, we observed that it is nearly 
impossible to predict the progression 
rate of asthma or chronic bronchitis 
from an assessm ent of symptoms, 
physical signs of the chest, and vari­
ability in PEFR. Patients at risk for 
rapid progression of their asthma or 
chronic bronchitis can probably be 
detected only by m onitoring the 
course of disease by assessing lung 
function. ■
C o r r e s p o n d e n c e  to :  C.R van Schayck, 
Department o f  General Practice, Nijmegen 
Universityy PO Box 9101, 6500 H B  Nijmegen3 
The Netherlands; phone: 0 0 3 1 -8 0 -6 1 5 3 1 3 3
fax: 0031-80-541862
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